GlassScriptPhysician profile
Ronit Juthani
NPI 1922786128
$1,416.69
in general payments reported to CMS, 2019-2025
23 companies · $516 in 2025
The $516 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $430 · 2024: $471 · 2025: $516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,417.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,416.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $420.42 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $140.40 | 2023-2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $90.19 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $77.00 | 2023-2024 | Entyvio |
| Fresenius Kabi USA, LLC | $70.99 | 2023-2024 | Idacio |
| Alexion Pharmaceuticals, INC. | $66.95 | 2023-2024 | Ultomiris |
| Novo Nordisk INC | $63.65 | 2023-2024 | Ozempic, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $55.53 | 2023-2025 | Opdivo |
| Grifols USA, LLC | $49.31 | 2024 | Gamunex-C |
| Glaxosmithkline, LLC. | $46.11 | 2023-2025 | Trelegy Ellipta, Nucala |
| Janssen Biotech, INC. | $41.82 | 2025 | Rybrevant |
| Alnylam Pharmaceuticals INC. | $40.42 | 2024 | Onpattro |
| Janssen Pharmaceuticals, INC | $31.10 | 2023 | Xarelto |
| Argenx US, INC. | $30.55 | 2024 | Vyvgart Hytrulo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.59 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $25.80 | 2024 | |
| Madrigal Pharmaceuticals | $24.41 | 2025 | Rezdiffra |
| Dexcom, INC. | $23.06 | 2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $20.91 | 2023 | |
| Alcresta Therapeutics, INC. | $19.09 | 2023 | Relizorb |
| Amgen INC. | $18.93 | 2025 | |
| Karyopharm Therapeutics INC. | $18.91 | 2024 | Xpovio |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $13.55 | 2025 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronit Juthani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.